MedTrace Logo

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

NCT00638963 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.

Conditions

  • Breast Neoplasm
  • Brain Neoplasm
  • Second Neoplasm

Interventions

DRUG

temozolomide

Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-02
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638963 on ClinicalTrials.gov